Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
CatalYm GmbH
Instituto do Cancer do Estado de São Paulo
7 Hills Pharma, LLC
Vivace Therapeutics, Inc
AstraZeneca
University Medical Center Groningen
Bristol-Myers Squibb
Sanofi
Inimmune Corporation
University of Kansas Medical Center
Vaxiion Therapeutics
University Hospital, Lille
Universitair Ziekenhuis Brussel